Skip to main content
. 2012 Nov 7;62(9):1340–1346. doi: 10.1136/gutjnl-2012-302553

Figure 3.

Figure 3

(A) The first-phase viral decline slope per day (Ph1/day) and (B) second-phase viral decline slope per week (Ph2/week) in hepatitis C virus (HCV) genotype 1-infected patients treated with pegylated interferon α plus ribavirin. The lines across the boxes indicate the median values. The hash marks above and below the boxes indicate the 90th and 10th percentiles for each group, respectively.